Published in Am J Med on February 01, 2009
Osteoporosis: now and the future. Lancet (2011) 5.81
Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int (2011) 3.04
Osteoporosis telephonic intervention to improve medication regimen adherence: a large, pragmatic, randomized controlled trial. Arch Intern Med (2012) 1.94
The relationship between bisphosphonate adherence and fracture: is it the behavior or the medication? Results from the placebo arm of the fracture intervention trial. J Bone Miner Res (2011) 1.70
Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis. Arthritis Res Ther (2011) 1.53
Discontinuation and reinitiation patterns of osteoporosis treatment among commercially insured postmenopausal women. Int J Gen Med (2013) 1.49
GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int (2011) 1.43
Increasing options for the treatment of osteoporosis. N Engl J Med (2009) 1.32
Hip fracture incidence is decreasing in the high incidence area of Oslo, Norway. Osteoporos Int (2012) 1.18
Patients' preferences for osteoporosis drug treatment: a discrete-choice experiment. Arthritis Res Ther (2014) 1.11
Adherence with intravenous zoledronate and intravenous ibandronate in the United States Medicare population. Arthritis Care Res (Hoboken) (2012) 1.09
The impact of teriparatide adherence and persistence on fracture outcomes. Osteoporos Int (2011) 1.09
Adherence and profile of non-persistence in patients treated for osteoporosis--a large-scale, long-term retrospective study in The Netherlands. Osteoporos Int (2010) 1.05
Bisphosphonate use and subsequent hip fracture in South Korea. Osteoporos Int (2013) 1.02
Placebo adherence, clinical outcomes, and mortality in the women's health initiative randomized hormone therapy trials. Med Care (2011) 1.00
Adherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors. Osteoporos Int (2010) 0.99
Partial adherence: a new perspective on health economic assessment in osteoporosis. Osteoporos Int (2011) 0.99
Persistence and switching patterns among women with varied osteoporosis medication histories: 12-month results from POSSIBLE US. Osteoporos Int (2010) 0.98
Evaluation of the osteogenic effect of low-level laser therapy (808 nm and 660 nm) on bone defects induced in the femurs of female rats submitted to ovariectomy. Lasers Med Sci (2011) 0.97
Bisphosphonate prescribing, persistence and cumulative exposure in Ontario, Canada. Osteoporos Int (2011) 0.96
Which Bisphosphonate? It's the Compliance!: Decision Analysis. J Bone Metab (2016) 0.96
Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study. Osteoporos Int (2014) 0.94
Measuring and improving adherence to osteoporosis pharmacotherapy. Curr Opin Rheumatol (2010) 0.93
Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management. Drug Healthc Patient Saf (2010) 0.92
Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study. Osteoporos Int (2015) 0.91
Does increased sunlight exposure work as a strategy to improve vitamin D status in the elderly: a cluster randomised controlled trial. Osteoporos Int (2011) 0.91
Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group. Osteoporos Int (2013) 0.90
The safety and effectiveness profile of daily teriparatide in a prospective observational study in Japanese patients with osteoporosis at high risk for fracture: interim report. J Bone Miner Metab (2013) 0.88
Management of osteoporosis of the oldest old. Osteoporos Int (2014) 0.87
Premenopausal women with a distal radial fracture have deteriorated trabecular bone density and morphology compared with controls without a fracture. J Bone Joint Surg Am (2013) 0.86
Osteoporosis pharmacotherapy following bone densitometry: importance of patient beliefs and understanding of DXA results. Osteoporos Int (2010) 0.86
Osteoporosis medication adherence: physician perceptions vs. patients' utilization. Bone (2013) 0.85
Cyclic tensile strain enhances osteogenesis and angiogenesis in mesenchymal stem cells from osteoporotic donors. Tissue Eng Part A (2013) 0.83
Bone turnover is adequately suppressed in osteoporotic patients treated with bisphosphonates in daily practice. BMC Musculoskelet Disord (2011) 0.83
Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy. Osteoporos Int (2013) 0.81
Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass. Drug Des Devel Ther (2010) 0.81
Improved real-life adherence of 6-monthly denosumab injections due to positive feedback based on rapid 6-month BMD increase and good safety profile. Rheumatol Int (2013) 0.81
The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis. Osteoporos Int (2013) 0.80
Appropriate use of anabolic treatment for severe osteoporosis. Clin Cases Miner Bone Metab (2010) 0.80
If you don't take it - it can't work: the consequences of not being treated or nonadherence to osteoporosis therapy. Ther Clin Risk Manag (2011) 0.80
Methods to examine the impact of compliance to osteoporosis pharmacotherapy on fracture risk: systematic review and recommendations. Ther Adv Chronic Dis (2010) 0.80
Synergistic antiosteoporotic effect of Lepidium sativum and alendronate in glucocorticoid-induced osteoporosis in Wistar rats. Afr J Tradit Complement Altern Med (2013) 0.80
Association between teriparatide treatment persistence and adherence, and fracture incidence in Taiwan: analysis using the National Health Insurance Research Database. Osteoporos Int (2016) 0.80
Single and combined effect of high-frequency loading and bisphosphonate treatment on the bone micro-architecture of ovariectomized rats. Osteoporos Int (2014) 0.79
GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab. Osteoporos Int (2016) 0.79
A cohort study of 4,190 patients treated with low-intensity pulsed ultrasound (LIPUS): findings in the elderly versus all patients. BMC Musculoskelet Disord (2015) 0.79
Non-adherence to anti-osteoporotic medications in Taiwan: physician specialty makes a difference. J Bone Miner Metab (2013) 0.79
Low bone mineral density and vitamin d deficiency correlated with genetics and other bone markers in female Turkish immigrants in Germany. Clin Rheumatol (2016) 0.79
Patient preference and acceptability of calcium plus vitamin D3 supplementation: a randomised, open, cross-over trial. Clin Rheumatol (2009) 0.79
Efficacy of ibandronate: a long term confirmation. Clin Cases Miner Bone Metab (2010) 0.79
Prevalence of osteoporosis in China: a meta-analysis and systematic review. BMC Public Health (2016) 0.78
Adherence to raloxifene therapy: assessment methods and relationship with efficacy. Osteoporos Int (2013) 0.78
Cost-effectiveness of raloxifene in the treatment of osteoporosis in Chinese postmenopausal women: impact of medication persistence and adherence. Patient Prefer Adherence (2016) 0.77
Does medication adherence itself confer fracture protection? An investigation of the healthy adherer effect in observational data. Arthritis Care Res (Hoboken) (2012) 0.77
Long-term persistence and switching patterns among women using osteoporosis therapies: 24- and 36-month results from POSSIBLE US™. Osteoporos Int (2014) 0.77
Rates and reasons for lack of persistence with anti-osteoporotic drugs: analysis of the Campania region database. Clin Cases Miner Bone Metab (2016) 0.76
Mechanical competence of ovariectomy-induced compromised bone after single or combined treatment with high-frequency loading and bisphosphonates. Sci Rep (2015) 0.76
Comparative Safety and Effectiveness of Denosumab Versus Zoledronic Acid in Patients With Osteoporosis: A Cohort Study. J Bone Miner Res (2016) 0.76
Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States. Osteoporos Int (2016) 0.75
Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States. Arch Osteoporos (2017) 0.75
Upper gastrointestinal tract transit times of tablet and drinkable solution formulations of alendronate: a bioequivalence and a quantitative, randomized study using video deglutition. Calcif Tissue Int (2012) 0.75
Gender- and age-related treatment compliance in patients with osteoporosis in Germany. Patient Prefer Adherence (2016) 0.75
A systematic literature review on the efficacy-effectiveness gap: comparison of randomized controlled trials and observational studies of glucose-lowering drugs. Clin Epidemiol (2017) 0.75
In Vivo Study on the Pharmacological Interactions between a Chinese Herbal Formula ELP and Antiresorptive Drugs to Counteract Osteoporosis. Evid Based Complement Alternat Med (2012) 0.75
Baseline Characteristics and Changes in Bone Mineral Density T-Scores of Bulgarian Women with Postmenopausal Osteoporosis Receiving Denosumab in Routine Clinical Practice. Drugs R D (2016) 0.75
Association between gastrointestinal events and compliance with osteoporosis therapy. Bone Rep (2015) 0.75
Comparison of orally administered bisphosphonate drugs in reducing the risk of hip fracture in older adults: a population-based cohort study. CMAJ Open (2013) 0.75
Can Alarming Improve Compliance with Weekly Bisphosphonate in Patients with Osteoporosis? J Bone Metab (2016) 0.75
A critical review of brand and generic alendronate for the treatment of osteoporosis. Springerplus (2013) 0.75
The role of galenic innovation in improving treatment compliance and persistence: three case studies. Clinicoecon Outcomes Res (2011) 0.75
Patient-reported reasons for nonadherence to recommended osteoporosis pharmacotherapy. J Am Pharm Assoc (2003) (2017) 0.75
Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years. Osteoporos Int (2017) 0.75
Persistence with denosumab therapy in women affected by osteoporosis with fragility fractures: a multicenter observational real practice study in Italy. J Endocrinol Invest (2017) 0.75
Medical specialty-related adherence to anti-osteoporotic regimens in fragility hip fracture patients. J Bone Miner Metab (2014) 0.75
Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium. Arch Osteoporos (2017) 0.75
Primary and secondary non-adherence to osteoporotic medications after hip fracture in Spain. The PREV2FO population-based retrospective cohort study. Sci Rep (2017) 0.75
Real-world clinical and economic outcomes for daily teriparatide patients in Japan. J Bone Miner Metab (2015) 0.75
Risk factors for fracture among current, persistent users of bisphosphonates. Osteoporos Int (2014) 0.75
Exploring methods for comparing the real-world effectiveness of treatments for osteoporosis: adjusted direct comparisons versus using patients as their own control. Arch Osteoporos (2017) 0.75
2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) (2012) 12.07
Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry (2007) 6.80
Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2007) 6.76
Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women's Health Study. Arthritis Rheum (2004) 4.77
American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) (2010) 4.65
2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) (2011) 3.66
Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA (2011) 3.58
Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken) (2012) 3.47
Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum (2007) 3.38
FRAX and its applications to clinical practice. Bone (2009) 3.32
Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc (2006) 2.96
The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res (2014) 2.52
Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA (2012) 2.51
Coffee, tea, and caffeine consumption and risk of rheumatoid arthritis: results from the Iowa Women's Health Study. Arthritis Rheum (2002) 2.43
Prescribing of rosiglitazone and pioglitazone following safety signals: analysis of trends in dispensing patterns in the Netherlands from 1998 to 2008. Drug Saf (2012) 2.36
Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res (2012) 2.29
Administrative codes combined with medical records based criteria accurately identified bacterial infections among rheumatoid arthritis patients. J Clin Epidemiol (2008) 2.25
Thiazide diuretics and the risk for hip fracture. Ann Intern Med (2003) 2.24
Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosis. J Bone Miner Res (2009) 2.24
Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum (2012) 2.15
Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic ThERapy (SABER) Study. Am J Ophthalmol (2012) 2.14
Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy. Arthritis Care Res (Hoboken) (2015) 2.03
Increased risk of achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids. Arch Intern Med (2003) 2.02
Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. Eur J Cancer (2005) 2.01
Re-using Mini-Sentinel data following rapid assessments of potential safety signals via modular analytic programs. Pharmacoepidemiol Drug Saf (2013) 2.01
Cigarette smoking and the risk of rheumatoid arthritis among postmenopausal women: results from the Iowa Women's Health Study. Am J Med (2002) 2.01
Obesity is not protective against fracture in postmenopausal women: GLOW. Am J Med (2011) 1.95
Trends in the use of biologic agents among rheumatoid arthritis patients enrolled in the US medicare program. Arthritis Care Res (Hoboken) (2013) 1.92
Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab (2006) 1.88
Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum (2006) 1.85
Using electronic health care records for drug safety signal detection: a comparative evaluation of statistical methods. Med Care (2012) 1.82
Effect of co-morbidities on fracture risk: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone (2012) 1.79
Quality of care indicators for gout management. Arthritis Rheum (2004) 1.77
Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch Intern Med (2004) 1.76
Measuring quality in arthritis care: methods for developing the Arthritis Foundation's quality indicator set. Arthritis Rheum (2004) 1.76
Randomized trial to improve fracture prevention in nursing home residents. Am J Med (2007) 1.75
Randomized trial of intensive bisphosphonate treatment versus symptomatic management in Paget's disease of bone. J Bone Miner Res (2010) 1.73
Increasing hip fracture incidence in California Hispanics, 1983 to 2000. Osteoporos Int (2004) 1.72
Agreement and validity of pharmacy data versus self-report for use of osteoporosis medications among chronic glucocorticoid users. Pharmacoepidemiol Drug Saf (2006) 1.65
Impact of prevalent fractures on quality of life: baseline results from the global longitudinal study of osteoporosis in women. Mayo Clin Proc (2010) 1.62
Validity of gout diagnoses in administrative data. Arthritis Rheum (2007) 1.62
Risk factors for treatment failure with antiosteoporosis medication: the global longitudinal study of osteoporosis in women (GLOW). J Bone Miner Res (2014) 1.62
Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients. Arthritis Rheum (2005) 1.58
The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol (2008) 1.58
Access to the Internet among drinkers, smokers and illicit drug users: is it a barrier to the provision of interventions on the World Wide Web? Med Inform Internet Med (2006) 1.56
Longitudinal trends in use of bone mass measurement among older americans, 1999-2005. J Bone Miner Res (2008) 1.55
Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. Arthritis Care Res (Hoboken) (2012) 1.53
Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis. Arthritis Res Ther (2011) 1.53
Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. Diabetes Care (2011) 1.52
OMERACT 6 brings new perspectives to rheumatology measurement research. J Rheumatol (2003) 1.47
Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J Bone Miner Res (2008) 1.47
Blood transfusion, alcohol use, and anthropometric risk factors for rheumatoid arthritis in older women. J Rheumatol (2002) 1.46
Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA (2013) 1.45
Quality of life of patients with irritable bowel syndrome is low compared to others with chronic diseases. Eur J Gastroenterol Hepatol (2006) 1.45
A 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: effects on bone density and fracture. Menopause (2015) 1.45
Identification and validation of vertebral compression fractures using administrative claims data. Med Care (2009) 1.45
Recent trends in hip fracture rates by race/ethnicity among older US adults. J Bone Miner Res (2012) 1.44
Does use of estrogens decrease the Breslow thickness of melanoma of the skin? Oral contraceptives and hormonal replacement therapy. Melanoma Res (2009) 1.43
Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum (2012) 1.43
The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. Ann Rheum Dis (2011) 1.42
Empirically based composite fracture prediction model from the Global Longitudinal Study of Osteoporosis in Postmenopausal Women (GLOW). J Clin Endocrinol Metab (2014) 1.41
Challenges in improving the quality of osteoporosis care for long-term glucocorticoid users: a prospective randomized trial. Arch Intern Med (2007) 1.41
Reversal in the secular trend of hip fracture incidences in Austria. Wien Klin Wochenschr (2010) 1.41
Population-based fracture risk assessment and osteoporosis treatment disparities by race and gender. J Gen Intern Med (2009) 1.40
Antioxidant micronutrients and risk of rheumatoid arthritis in a cohort of older women. Am J Epidemiol (2003) 1.35
Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther (2006) 1.32
Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Ann Rheum Dis (2012) 1.31
Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis. Med Care (2009) 1.31
Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems. Pharmacoepidemiol Drug Saf (2011) 1.30
Previous fractures at multiple sites increase the risk for subsequent fractures: the Global Longitudinal Study of Osteoporosis in Women. J Bone Miner Res (2012) 1.29
The economic burden of depression in Sweden from 1997 to 2005. Eur Psychiatry (2006) 1.28
Central DXA utilization shifts from office-based to hospital-based settings among medicare beneficiaries in the wake of reimbursement changes. J Bone Miner Res (2012) 1.27
Enhanced persistence with tiotropium compared with other respiratory drugs in COPD. Respir Med (2007) 1.27
Drug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum (2007) 1.26
Incidence and determinants of long-term use of antidepressants. Eur J Clin Pharmacol (2004) 1.25
New opportunities for drug outcomes research in cancer patients: the linkage of the Eindhoven Cancer Registry and the PHARMO Record Linkage System. Eur J Cancer (2009) 1.23
Predicting fractures in an international cohort using risk factor algorithms without BMD. J Bone Miner Res (2011) 1.22
Treatment of rheumatoid arthritis. Am J Health Syst Pharm (2006) 1.21
Health services utilization after fractures: evidence from Medicare. J Gerontol A Biol Sci Med Sci (2010) 1.19
Relationship of weight, height, and body mass index with fracture risk at different sites in postmenopausal women: the Global Longitudinal study of Osteoporosis in Women (GLOW). J Bone Miner Res (2014) 1.19
Health care expenditures associated with skeletal fractures among Medicare beneficiaries, 1999-2005. J Bone Miner Res (2009) 1.18
Undertreatment with anti-osteoporotic drugs after hospitalization for fracture. Osteoporos Int (2003) 1.17
Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis. Curr Med Res Opin (2008) 1.14
Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis. Breast Cancer Res Treat (2010) 1.13
Racial disparities in the receipt of osteoporosis related healthcare among community-dwelling older women with arthritis and previous fracture. J Rheumatol (2005) 1.12
Quality indicators for the care of osteoarthritis in vulnerable elders. J Am Geriatr Soc (2007) 1.12
Psoriasis may not be an independent risk factor for acute ischemic heart disease hospitalizations: results of a large population-based Dutch cohort. J Invest Dermatol (2009) 1.11
Gout-related health care utilization in US emergency departments, 2006 through 2008. Arthritis Care Res (Hoboken) (2013) 1.10
Racial disparities in osteoporosis prevention in a managed care population. South Med J (2003) 1.10
Developing a provisional definition of flare in patients with established gout. Arthritis Rheum (2012) 1.10
Inappropriate initial treatment of secondary intra-abdominal infections leads to increased risk of clinical failure and costs. Br J Clin Pharmacol (2005) 1.10
Using a modified nominal group technique to elicit director of nursing input for an osteoporosis intervention. J Am Med Dir Assoc (2006) 1.10
Potential and pitfalls of using large administrative claims data to study the safety of osteoporosis therapies. Curr Rheumatol Rep (2011) 1.10
Adherence with intravenous zoledronate and intravenous ibandronate in the United States Medicare population. Arthritis Care Res (Hoboken) (2012) 1.09
Determination of non-treatment with statins of high risk patients in The Netherlands. Curr Med Res Opin (2010) 1.09
Differences in antihypertensive drug persistence associated with drug class and gender: a PHARMO study. Pharmacoepidemiol Drug Saf (2005) 1.09
The PAADRN study: a design for a randomized controlled practical clinical trial to improve bone health. Contemp Clin Trials (2012) 1.09
Estrogen and other female reproductive risk factors are not strongly associated with the development of rheumatoid arthritis in elderly women. Semin Arthritis Rheum (2003) 1.07
The costs of benzodiazepine-associated hospital-treated fall Injuries in the EU: a Pharmo study. Drugs Aging (2003) 1.06
Pathophysiology, clinical presentation and treatment of gout. Drugs (2006) 1.06